UniQure, Syndax, Erasca Drawing Fresh Analyst Interest
Three clinical-stage biotechs—UniQure, Syndax, and Erasca—are catching analyst attention ahead of key catalysts, with...
Index levels shift due to earnings, valuations, and macro surprises. Knowing the main drivers helps you anticipate potential reversals.
17,383 articlesThree clinical-stage biotechs—UniQure, Syndax, and Erasca—are catching analyst attention ahead of key catalysts, with...
Bitcoin, Ethereum and XRP anchor a choppy session as policymakers weigh new rules and traders parse liquidity and ris...
Quantum computing is approaching a pivotal moment. This article lays out why the thesis 'prediction: ionq will first'...
Evergreen demand makes certain stocks thrive through booms and busts. Learn how these consumer staples stocks stay re...
The Trump administration uses the Defense Production Act to compel the restart of offshore California oil operations,...
Micron Technology sits at the intersection of memory chips and AI demand. This guide examines whether you should micr...
Team (TISI) kicks off 2025 with a solid Q1 showing that blends growing customer demand with margin challenges. This a...
U.S. equities fell Friday as oil surged to $110 a barrel, stoking inflation worries and shaping expectations for mone...
Dollar Tree has reshaped its business with store expansion and a strategic divestment. This guide explains why you mi...
Firefly Aerospace surprised investors with a better-than-expected Q4 result, sending its stock higher before ending t...
A notable fund trimmed a sizable healthcare stake by roughly $6.5 million as the stock soared and revenue grew. Here’...
A respected Wall Street voice argues for a bold bitcoin target. This guide breaks down the reasoning, checks the math...